Performance Evaluation of the Fujifilm Wako Beta-D-glucan Technique in the Diagnosis of Major Invasive Fungal Infections (IFI)

Central Hospital, Nancy, France

Status

Completed

Conditions

Pneumocystosis; Pneumonia (Etiology)

Candidemia

IFI

Aspergillosis Invasive

Treatments

Diagnostic Test: Beta-1,3/1,6-D-Glucan

Study type

Observational

Funder types

Other

Identifiers

NCT07272915

2024PI143

Details and patient eligibility

About

Invasive fungal infections (IFI) are a major concern for immunocompromised or vulnerable patients. Associated mortality is significant and depends on the timeliness of diagnostic and therapeutic management. Consequently, biomarkers play a key role in therapeutic strategies compared to conventional phenotypic techniques, due to their shorter turnaround time. Beta-D-glucan (BDG) is a pan-fungal serum marker that enables the detection of invasive fungal infections (primarily candidiasis, aspergillosis, and pneumocystosis). This marker was initially introduced by CapeCod, and most studies are based on this test. More recently, the Wako test has been proposed and implemented in our center.

Our study aims to report our experience using the Wako test for BDG measurement, focusing on true and false positives.

The objective is to estimate the test performance, within the patient population, and the percentage of confirmed IFI diagnoses when at least two positive Wako test results are observed in the same patient within a consecutive 15-day period.

Enrollment

280 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria